Sanofi
An institutional investment manager in Paris. Its Form 13F for the quarter ended Jun 30, 2026, filed Jul 28, 2026. SEC CIK 1121404.
- Reported value$534.0m
- Positions10
Holdings: 10 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| MeiraGTx Holdings plc | COM | G59665102 | 165 | 30.9% | 12,197,737 | Unchanged | |
| Inhibrx Biosciences, Inc.INBX | COM | 45720N103 | 110 | 20.5% | 1,157,926 | Unchanged | |
| NovavaxNVAX | COM NEW | 670002401 | 64.8 | 12.1% | 6,880,481 | Unchanged | |
| AnaptysBioANAB | COM | 032724106 | 55.5 | 10.4% | 821,917 | Unchanged | |
| Odyssey Therapeutics Inc.ODTX | COMMON STOCK | 67613T104 | 37.3 | 7.0% | 1,991,918 | New+1,991,918 | |
| Agomab Therapeutics NVAGMB | SPONSORED ADS | 00860C102 | 36.1 | 6.8% | 2,783,096 | Unchanged | |
| MapLight Therapeutics Inc.MPLT | COM | 56565P103 | 32.7 | 6.1% | 912,041 | Unchanged | |
| First Tracks Biotherapeutics Inc.TRAX | ORD SHS | 337185102 | 16.5 | 3.1% | 821,917 | New+821,917 | |
| Immuneering CorpIMRX | CLASS A COM | 45254E107 | 13.5 | 2.5% | 2,708,559 | Unchanged | |
| Q32 Bio Inc.QTTB | COM | 746964105 | 3.1 | 0.6% | 244,083 | Unchanged |
Sold out: 1 position
Held at the end of the quarter before and not reported this quarter.
| Issuer | Class | CUSIP | Reported value$ | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| EledonELDN | COM | 28617K101 | 0.0 | 0.0% | 0 | Sold out−814,980 |
Source: SEC EDGAR, Form 13F-HR, accession 0001193125-26-318812 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.